NxGen founder fires back at Penn and Dr. James Wilson in lawsuit over 'decade-long nightmare'
The one-time postdoctoral researcher alleges her "life ’s work is being held hostage" by Penn and Dr. James Wilson, director of the university's gene therapy program. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - April 25, 2024 Category: Pharmaceuticals Authors: John George Source Type: news
Cell and Gene Therapy Development: Characterization of Cellular Source Material, Upcoming Webinar Hosted by Xtalks
In this free webinar, gain insights into characterizing cellular source material for developing and manufacturing cell and gene therapy-based products. Attendees will learn about intrinsic and external factors that influence cell variability in donors with the desired target profile, and... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - April 25, 2024 Category: Pharmaceuticals Source Type: news
Auchincloss to keynote rare disease innovation forum
The Massachusetts congressman has been an advocate for biotech investment, R&D, and broader access to gene therapies. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - April 19, 2024 Category: Pharmaceuticals Authors: Mary Serreze Source Type: news
Gene Therapy: Non-Viral Vectors
Modern medicine constantly searches for safer and more efficient ways to treat genetic disorders. One cutting-edge solution that has emerged is the use of non-viral vectors. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - April 18, 2024 Category: Pharmaceuticals Authors: William A. Haseltine, Contributor Tags: Healthcare /healthcare Innovation /innovation business pharma & standard Source Type: news
Gene Therapy Methods Explained
Gene delivery systems are critical for gene therapy and can be classified as viral or non-viral vectors. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - April 16, 2024 Category: Pharmaceuticals Authors: William A. Haseltine, Contributor Tags: Healthcare /healthcare Innovation /innovation business pharma & standard Source Type: news
AskBio presents 18-month Phase Ib trial results of AB-1005 gene therapy for patients with Parkinson & #039;s disease
Bayer AG and Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, on Sunday April 14 presented results from the 18-month Phase Ib clinical trial for AB-1005, an investigational gene therapy for treating patients with Parkinson's disease (PD).(1,2) The data were presented at the American Academy of Neurology 2024 Annual Meeting in Denver, Colorado, USA.
The study met its primary objective, which was to evaluate the safety of a one-time bilateral delivery of AB-1005 directly to the putamen. (Source: World Pharma News)
Source: World Pharma News - April 16, 2024 Category: Pharmaceuticals Tags: Featured Bayer Business and Industry Source Type: news
Mayo Clinic RegenBio Summit 2024 registration opens, keynotes announced
Gene editing, gene therapy and tissue engineering are emerging regenerative biotherapies that are on the cusp of transforming medical care. RegenBio Summit: Transforming Next-Gen Biotherapeutics 2024, will focus on accelerating technologies from concept to reality for patients in need of new healing options. Register now to join physicians, scientists, general healthcare staff, industry leaders and students from Dec. 9 to 11 at the Ponte Vedra Inn& Club in Ponte Vedra Beach, Florida. Regenerative biotherapies… (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - April 15, 2024 Category: Databases & Libraries Source Type: news
AskBio co-founder Jude Samulski steps down, successor named
The groundbreaking co-founder of one of North Carolina's most well-known gene therapy companies has left his longtime role in the C-suite. He's replaced by a prominent executive from Eli Lilly and Co. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - April 9, 2024 Category: Pharmaceuticals Authors: Zac Ezzone Source Type: news
Regulatory Education for Industry (REdI) Annual Conference 2024: Biologics Track
The Biologics Track will focus on the developmental and regulatory topics relevant to cellular and gene therapies, tissue-engineered products, blood products, vaccines, and other biological products. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - April 8, 2024 Category: Drugs & Pharmacology Authors: FDA Source Type: news
OCGN Stock Alert: Why Is Ocugen Up 20% Today?
Biotechnology firm Ocugen (NASDAQ:OCGN) — which specializes in developing gene therapies to address blindness diseases — saw its shares move higher on an encouraging clinical development. An advisory committee responsible for overseeing safety matters approved Ocugen to use a medium dosage of its…#ocugen #dsmb #peterchang #dsmbchair #ocgn #amd #joshenomoto (Source: Reuters: Health)
Source: Reuters: Health - April 5, 2024 Category: Consumer Health News Source Type: news
Heart-1 Gene Therapy Trial Pauses Enrollment Heart-1 Gene Therapy Trial Pauses Enrollment
A phase 1 gene editing trial in patients with heterozygous familial hypercholesterolemia and atherosclerotic CVD was paused after abnormal lab results were seen.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - April 4, 2024 Category: Cardiology Tags: Cardiology Source Type: news
Gene Therapy, DNA's Past, RNA's Future: The Golden Era
Gene therapy made significant breakthroughs between 2000 and the 2010s, marking a golden era in medical history. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - April 2, 2024 Category: Pharmaceuticals Authors: William A. Haseltine, Contributor Tags: Healthcare /healthcare Innovation /innovation business pharma & standard Source Type: news
Groundbreaking gene therapy offers ‘glimmer of hope’ for children with rare diseases
Within the first few weeks after Lori and Lee Greenwood ’s daughter Noa was born, her parents knew that something was wrong. A lot of different things, actually. The infant cried inconsolably. She wouldn’t follow her parents with her eyes, leading to concerns about her vision. She struggled to gain weight and missed milestone after milestone. She was slow to even respond to her parents’ presence.
After weeks and months of having doctors dismiss it as the normal fits and fuss of a newborn, the… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - April 1, 2024 Category: Pharmaceuticals Authors: UMass Chan Medical School Source Type: news
Seattle Children's receives $50 million gift for pediatric cancer research
The gift from the William Lawrence and Blanche Hughes Foundation will be used to develop treatments for childhood cancers using cell and gene therapies. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - March 28, 2024 Category: Pharmaceuticals Authors: Rick Morgan Source Type: news
Gene therapy from RTP biotech improves vision in clinical study
After spending most of their lives nearly totally blind, a few patients can see objects for the first time after receiving a gene therapy being developed by a biotech in Research Triangle Park. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - March 28, 2024 Category: Biotechnology Authors: Zac Ezzone Source Type: news
